Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
Acadia Pharmaceuticals to report Q3 financial results and host conference call
Positive
Acadia Pharmaceuticals will report its third quarter financial results on November 2, 2023.
The company's management team will host a conference call and webcast to discuss financial results and operations.
The conference call will be available on Acadia's website and will be archived until December 4, 2023.
10/19/2023 - 04:05 PM
Company to host conference call and webcast on Thursday, November 2, 2023, at 4:30 p.m. Eastern Time
SAN DIEGO --(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
The conference call will be available on Acadia’s website, www.acadia.com under the investors section and will be archived there until December 4, 2023. The conference call may also be accessed by registering for the call here . Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20231019859462/en/
Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
When will Acadia Pharmaceuticals report its third quarter financial results?
Acadia Pharmaceuticals will report its third quarter financial results on November 2, 2023.
What will be discussed during the conference call and webcast?
The conference call and webcast will discuss Acadia Pharmaceuticals' financial results and operations.
Where can I access the conference call?
The conference call can be accessed on Acadia Pharmaceuticals' website.
How long will the conference call be available for?
The conference call will be archived on Acadia Pharmaceuticals' website until December 4, 2023.
Acadia Pharmaceuticals Inc
ACAD Rankings
#572 Ranked by Stock Gains
ACAD Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About ACAD
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies